首页> 外文期刊>Cell >A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential
【24h】

A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential

机译:对Zika病毒具有高治疗潜力的人类双特异性抗体

获取原文
获取原文并翻译 | 示例
           

摘要

Zika virus (ZIKV), a mosquito-borne flavivirus, causes devastating congenital birth defects. We isolated a human monoclonal antibody (mAb), ZKA190, that potently cross-neutralizes multi-lineage ZIKV strains. ZKA190 is highly effective in vivo in preventing morbidity and mortality of ZIKV-infected mice. NMR and cryo-electron microscopy show its binding to an exposed epitope on DIII of the E protein. ZKA190 Fab binds all 180 E protein copies, altering the virus quaternary arrangement and surface curvature. However, ZIKV escape mutants emerged in vitro and in vivo in the presence of ZKA190, as well as of other neutralizing mAbs. To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a second mAb specific for DII of E protein. In addition to retaining high in vitro and in vivo potencies, FIT-1 robustly prevented viral escape, warranting its development as a ZIKV immunotherapy.
机译:Zika病毒(ZIKV)是一种蚊子的黄病毒,导致毁灭性的先天性缺陷。 我们孤立一种人单克隆抗体(MAB),ZKA190,其高度交叉中和多谱系ZIKV菌株。 ZKA190在体内非常有效地预防ZIKV感染的小鼠的发病率和死亡率。 NMR和Cryo-Electronic显微镜显示其与E蛋白的DIII上的暴露表位的结合。 ZKA190 Fab结合所有180份E蛋白质复印件,改变病毒季度排列和表面曲率。 然而,Zikv逃生突变体在ZKA190存在下在体外和体内出现,以及其他中和mAb。 为了解决这个问题,我们开发了一种具有ZKA190的双特异性抗体(FIT-1)和特异于E蛋白的DII的第二MAb。 除了保留高体外和体内疗效外,FIT-1鲁棒地防止病毒逃生,保证其作为ZIKV免疫疗法的发展。

著录项

  • 来源
    《Cell》 |2017年第1期|共28页
  • 作者单位

    Duke Natl Univ Singapore Program Emerging Infect Dis Med Sch Singapore 169857 Singapore;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Univ Calif Berkeley Div Infect Dis &

    Vaccinol Sch Publ Hlth Li Ka Shing Ctr 185 1951 Oxford St Berkeley CA 94720 USA;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Duke Natl Univ Singapore Program Emerging Infect Dis Med Sch Singapore 169857 Singapore;

    Humabs BioMed SA Via Mirasole 1 CH-6500 Bellinzona Switzerland;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Duke Natl Univ Singapore Program Emerging Infect Dis Med Sch Singapore 169857 Singapore;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Humabs BioMed SA Via Mirasole 1 CH-6500 Bellinzona Switzerland;

    Humabs BioMed SA Via Mirasole 1 CH-6500 Bellinzona Switzerland;

    Humabs BioMed SA Via Mirasole 1 CH-6500 Bellinzona Switzerland;

    Humabs BioMed SA Via Mirasole 1 CH-6500 Bellinzona Switzerland;

    Duke Natl Univ Singapore Program Emerging Infect Dis Med Sch Singapore 169857 Singapore;

    Natl Univ Singapore Ctr BioImaging Sci Singapore 117557 Singapore;

    Univ Calif Berkeley Div Infect Dis &

    Vaccinol Sch Publ Hlth Li Ka Shing Ctr 185 1951 Oxford St Berkeley CA 94720 USA;

    Ist Sci San Raffaele Viral Pathogens &

    Biosafety Unit Via Olgettina 58 I-20132 Milan Italy;

    Ist Sci San Raffaele Viral Pathogens &

    Biosafety Unit Via Olgettina 58 I-20132 Milan Italy;

    Ist Sci San Raffaele Viral Pathogens &

    Biosafety Unit Via Olgettina 58 I-20132 Milan Italy;

    Ist Sci San Raffaele Viral Pathogens &

    Biosafety Unit Via Olgettina 58 I-20132 Milan Italy;

    Publ Hlth England Natl Infect Serv Salisbury Wilts England;

    Publ Hlth England Natl Infect Serv Salisbury Wilts England;

    Publ Hlth England Natl Infect Serv Salisbury Wilts England;

    Publ Hlth England Natl Infect Serv Salisbury Wilts England;

    Univ Zurich Dept Chem Zurich Switzerland;

    Univ Zurich Dept Chem Zurich Switzerland;

    Humabs BioMed SA Via Mirasole 1 CH-6500 Bellinzona Switzerland;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Univ Calif Berkeley Div Infect Dis &

    Vaccinol Sch Publ Hlth Li Ka Shing Ctr 185 1951 Oxford St Berkeley CA 94720 USA;

    Duke Natl Univ Singapore Program Emerging Infect Dis Med Sch Singapore 169857 Singapore;

    Univ Svizzera Italiana Inst Res Biomed Via Vincenzo Vela 6 CH-6500 Bellinzona Switzerland;

    Humabs BioMed SA Via Mirasole 1 CH-6500 Bellinzona Switzerland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号